KIF11 and neoplasm: Eg5 is overexpressed in a variety of malignant tumors and is barely detectable in normal tissues, making it an ideal target for anticancer drugs that can specifically inhibit tumor cells while minimizing the impact on normal cells [21,22,23,24].